Differences in Lipid Profiles of Patients Given Rosiglitazone Followed by Pioglitazone

References

• Mudaliar S, Henry RR. New oral therapies for type 2 diabetes mellitus: the glitazones or insulin sensitizers. In: Caskey CT, Austin C, Hoxie J, eds. Annual Review of Medicine: Selected Topics in the Clinical Sciences. Palo Alto, CA: Annual Reviews 2001;52: 239–57
   Google Scholar
• Bressler R, Johnson DG. Pharmacological regulation of blood glucose levels in non-insulin-dependent diabetes mellitus. Arch Intern Med 1997;157:836–48
   PubMed Web of Science ®Google Scholar
• Gegick CG, Altheimer MD. Comparison of effects of thiazolidinediones on cardiovascular risk factors: observations from a clinical practice. Endocr Pract 2001;7:162–9
   PubMedGoogle Scholar
• King AB. A comparison in a clinical setting of the efficacy and side effects of three thiazolidinediones. Diabetes Care 2000;23:557
   PubMed Web of Science ®Google Scholar
• Khan MA, St. Peter JV, Xue JL. A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. Diabetes Care 2002;25:708–11
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Clinical practice recommendations 2001. Diabetes Care 2001;23(Suppl 1):S1–121
   Google Scholar
• American Association of Clinical Endocrinologists. The American Association of Clinical Endocrinologists medical guidelines for the management of diabetes mellitus: the AACE system of intensive diabetes self-management: 2002 update. Endocr Pract 2002;8:40–82
   PubMedGoogle Scholar
• Akazawa S, Sun F, Ito M, Kawasaki E, Eguchi K. Efficacy of troglitazone on body fat distribution in type 2 diabetes. Diabetes Care 2000;23: 1067–71
   PubMed Web of Science ®Google Scholar
• Barnett AH. Insulin-sensitizing agents – thiazolidinediones (glitazones). Curr Med Res Opin 2002;18(1):S31–9
   Google Scholar
• Nitiyanant W, Tandhanand S, Mahtab H, et al. The Diabcare-Asia 1998 study – outcomes on control and complications in type 1 and type 2 diabetic patients. Curr Med Res Opin 2002;18:317–27
   PubMed Web of Science ®Google Scholar
• Papadakis JA, Milionis HJ, Press M, Mikhailidis DP. Treating dyslipidaemia in non-insulin-dependent diabetes mellitus – a special reference to statins. J Diabetes Complications 2001;15:211–26
   PubMed Web of Science ®Google Scholar
• Howard BV. Lipoprotein metabolism in diabetes mellitus. J Lipid Res 1987;28:613–28
   PubMed Web of Science ®Google Scholar
• Barakat HA, Carpenter JW, McLendon VD, et al. Influence of obesity, impaired glucose tolerance, and NIDDM on LDLC structure and composition: possible link between hyperinsulinemia and atherosclerosis. Diabetes 1990;39:1527–33
   PubMed Web of Science ®Google Scholar
• Chen YDI, Jeng CY, Reaven GM. HDL-C metabolism in diabetes. Diabetes Metab Rev 1987;3:653–68
   PubMed Web of Science ®Google Scholar
• Sunayama S, Watanabe Y, Daida H, Yamaguchi H. Thiazolidinediones, dyslipidemia, and insulin resistance syndrome. Curr Opin Lipidol 2000;11:397–402
   PubMed Web of Science ®Google Scholar
• Sunayama S, Watanabe Y, Ohmura H, et al. Effects of troglitazone on atherogenic lipoprotein phenotype in coronary patients with insulin resistance. Atherosclerosis 1999;146:187–93
   PubMed Web of Science ®Google Scholar
• Henry RR. Thiazolidinediones. Endocrin Metab Clin North Am 1997;26:553–72
   PubMed Web of Science ®Google Scholar
• Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA 2000;283:1695–702
   PubMed Web of Science ®Google Scholar
• Phillips LS, Grunberger G, Miller E, et al. Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabetes Care 2001;24:308–15
   PubMed Web of Science ®Google Scholar
• Patel J, Anderson RJ, Rappaport EB. Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study. Diabetes Obes Metab 1999;1: 165–72
   PubMed Web of Science ®Google Scholar
• Wolffenbuttel BHR, Gomist R, Squatrito S, Jones NP, Patwardhan RN. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in type 2 diabetic patients. Diabet Med 2000;17: 40–47
   PubMed Web of Science ®Google Scholar
• Nolan JJ, Jones NP, Patwardhan R, Deacon LF. Rosiglitazone taken once daily provides effective glycaemic control in patients with type 2 diabetes mellitus. Diabet Med 2000;17:287–94
   PubMed Web of Science ®Google Scholar
• Rosenblatt S, Miskin B, Glazer NB, Prince MJ, Robertson KE, Pioglitazone 026 Study Group. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitis. Coron Artery Dis 2001;12: 413–23
   PubMed Web of Science ®Google Scholar
• Aronoff S, Mathisen AL, Rosenblatt S, et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study. Diabetes Care 2000;23:1605–11
   PubMed Web of Science ®Google Scholar
• Einhorn D, Rendell M, Rosenzweig J, et al. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group. Clin Ther 2000;22:1395–409
   PubMed Web of Science ®Google Scholar
• Kipnes MS, Krosnick A, Rendell MS, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am J Med 2001;111:10–17
   PubMed Web of Science ®Google Scholar
• Miyazaki Y, Ferrannini E, Mahankali A, et al. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 2001;24:710–19
   PubMed Web of Science ®Google Scholar
• Baba S. Pioglitazone: a review of Japanese clinical studies. Curr Med Res Opin 2001;17:166–89
   PubMed Web of Science ®Google Scholar
• Sacks FM. The relative role of low-density lipoprotein cholesterol and high-density lipoprotein cholesterol in coronary artery disease: evidence from large-scale statin and fibrin trials. Am J Cardiol 2001;88:14–18N
   PubMed Web of Science ®Google Scholar
• Rubins HB, Robins SJ, Collins D, et al. The Veterans Affairs High-density lipoprotein cholesterol Intervention Trial study group (VA-HIT): gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med. 1999;341;410–18
   PubMed Web of Science ®Google Scholar
• Prince MJ, Zagar AJ, Robertson KE. Effect of pioglitazone on HDL-C, a cardiovascular risk factor in type 2 diabetes. Diabetes 2001;50(Suppl 2):A128
   Google Scholar
• Parulkar AA, Pendergrass ML, Granda-Ayala R, Lee TR, Fonseca VA. Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med 2001;134:61–71
   PubMed Web of Science ®Google Scholar
• Winkler K, Friedrich I, Nauck M, Wieland H, Maerz W. Pioglitazone reduces dense LDL-particles in patients with type-2 diabetes. Diabetes 2001;50(Suppl 2):A147
   Google Scholar
• Tan M, Johns D, Glazer B, Pioglitazone 001 Study Group. Pioglitazone reduces atherogenic index of plasma, an indirect indicator of LDL particle size. Diabetes 2001;50(Suppl 2):A133
   Google Scholar
• Brunzell J, Cohen B, Kreider M, et al. Rosiglitazone favorably affects LDL-C and HDL-C heterogeneity in type 2 diabetes. Diabetes 2001;50(Suppl 2):A141
   Google Scholar
• Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486–97
   PubMed Web of Science ®Google Scholar
• Athyros VG, Papageorgiou AA, Mercouris BR, et al. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus “usual” care in secondary coronary heart disease prevention: the GREek atorvastatin and coronary-heart-disease evaluation (GREACE) study. Curr Med Res Opin 2002;18:220–8
   PubMed Web of Science ®Google Scholar
• Smith U. Pioglitazone: mechanism of action. Int J Clin Pract 2001;Sep:13–18
   Web of Science ®Google Scholar
• Guan Y, Breyer MD. Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease. Kidney Int 2001;60:14–30
   PubMed Web of Science ®Google Scholar
• Sakamto J, Kimura H, Moriyama S, et al. Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone. Biochem Biophys Res Commun 2000; 278:704–11
   PubMed Web of Science ®Google Scholar